Date: 2017-01-16
Type of information: Nomination
Compound: scientific advisory board
Company: Oryzon Genomics (Spain)
Therapeutic area: Neurodegenerative diseases - Neuroinflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 16, 2017, Oryzon Genomics announced key additions to its Scientific Advisory Board (SAB) to reinforce the capabilities of its epigenetic drug ORY-2001 in neurodegenerative and neuroinflammatory diseases, a drug for which a phase 1 clinical trial is expected to be completed this year.
- The new members are:
- Professor Howard Fillit is an internationally recognized geriatrician and neuroscientist and expert in Alzheimer's disease. He is the Founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation. Dr. Fillit has held faculty positions at The Rockefeller University, the SUNY-Stony Brook School of Medicine and the Cornell University School of Medicine. In 1987, he joined the Mount Sinai School of Medicine, where he is now a clinical professor of geriatric medicine and palliative care, medicine and neuroscience at the Icahn School of Medicine. He is the author or coauthor of more than 300 scientific articles, abstracts and books, including the leading international Brocklehurst’s Textbook of Geriatric Medicine and Gerontology currently in its 8th edition.
- José Luis Molinuevo is an internationally reputed neurologist specialized in AD, PD and related disorders. He was the Director of the Alzheimer’s disease Unit at the Hospital Clínic of Barcelona and now he is the scientific director of the Barcelonabeta Brain Research Center of the Pasqual Maragall Foundation. He is a member of the European Alzheimer Disease Consortium, of the dementia panel for the European Association of Neurology, and of the Alzheimer Biomarker Standarization Initiative (ABSI). He is the Spanish coordinator of the BIOMARKAPD of the Joint Programming on Neurodegenerative Diseases, co-lead and partner of several Innovative Medicine Initiative consortiums and part of the International Working Group and the National Institute on Aging-Alzheimer’s Association (NIA-AA) groups for developing new research criteria.
The Scientific Advisory Board also includes other CNS specialists: Professor Harald Hampel, MD a world authority on Alzheimer’s disease and related neurodegenerative diseases. He is Professor and AXA Research Fund and UPMC Chair at the Sorbonne Universities, Pierre and Marie Curie University (UPMC) in Paris, France, Professor Xavier Montalban, president of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Chairman of the International Medical & Scientific
Board of the Multiple Sclerosis International Federation (MSIF) and Professor Isidro Ferrer, a renowned neuropathologist and Director of the Institute of Neuropathology at the Bellvitge Hospital in Barcelona.
- The SAB is functioning as a strategic network of scientific, medical and clinical experts to Oryzon as the company progresses the development of its pipeline in epigenetics and will be in position to initiate phase II trials with its lead candidate ORY-2001 in neurodegenerative disorders in the near future.
Financial terms:
Latest news:
Is general: Yes
